- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01911715
A Study to Explore the Routes of Elimination of MDV3100
A Phase I Open-label Study to Investigate the Mass Balance and Biotransformation of a Single Oral 160 mg (100 µCi) Dose of 14C-MDV3100 (ASP9785) in Healthy Male Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Zuidlaren, Netherlands, 9471GP
- PRA International
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body Mass Index within 18.5 to 30.0kg/m2
- Regular defecation pattern (minimum once per 2 days).
- Subject must be non-fertile, i.e., surgically sterilized or must practice an adequate contraceptive method to prevent pregnancies as defined in the protocol.
Exclusion Criteria:
- Known or suspected hypersensitivity to MDV3100, or any components of the formulation used.
- Any of the liver function tests above the upper limit of normal. A retest to confirm the result may be performed once.
- Any clinically significant history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any drug (excluding non-active hay fever).
- Abnormal pulse and/or blood pressure measurements at the pre-study visit as follows: Pulse <40 or >90 bpm; mean systolic blood pressure >140 mmHg ; mean diastolic blood pressure >90 mmHg (blood pressure measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically).
- A QTc interval of > 430 ms after repeated measurements (consistently after duplicate measurements), a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS).
- Use of any prescribed or OTC (over-the-counter) drugs (including vitamins, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the Clinical Unit, except for occasional use of paracetamol (up to 3 g/day).
- Regular use of any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit.
- Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.
- Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton (excluding spinal column)), during work or during participation in a clinical study in the previous year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Single Oral MDV3100 dose
|
Oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Maximum concentration (Cmax)
Time Frame: Day 1 through Day 78 (21 times)
|
Day 1 through Day 78 (21 times)
|
|
Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Time to attain Cmax (tmax)
Time Frame: Day 1 through Day 78 (21 times)
|
Time to attain Cmax (tmax)
|
Day 1 through Day 78 (21 times)
|
Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Time to reach quantifiable concentrations (tlag)
Time Frame: Day 1 through Day 78 (21 times)
|
Day 1 through Day 78 (21 times)
|
|
Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by AUC from the time of dosing to the last measurable concentration (AUC0-t)
Time Frame: Day 1 through Day 78 (21 times)
|
Day 1 through Day 78 (21 times)
|
|
Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by AUC extrapolated to infinity (AUC0-inf)
Time Frame: Day 1 through Day 78 (21 times)
|
Day 1 through Day 78 (21 times)
|
|
Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Terminal Disposition Rate Constant (λz)
Time Frame: Day 1 through Day 78 (21 times)
|
Day 1 through Day 78 (21 times)
|
|
Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Apparent terminal elimination half life (t1/2)
Time Frame: Day 1 through Day 78 (21 times)
|
Day 1 through Day 78 (21 times)
|
|
Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Apparent total body clearance after extra vascular dosing (CL/F)
Time Frame: Day 1 through Day 78 (21 times)
|
Day 1 through Day 78 (21 times)
|
|
Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by Apparent volume of distribution during the terminal phase after extra vascular dosing (Vz/F)
Time Frame: Day 1 through Day 78 (21 times)
|
Day 1 through Day 78 (21 times)
|
|
Assessment of Pharmacokinetic profile of total radioactivity in plasma and whole blood by blood-to-plasma ratio (Ratio Cb/p)
Time Frame: Day 1 through Day 78 (21 times)
|
Day 1 through Day 78 (21 times)
|
|
Assessment of 14C recovery in urine
Time Frame: Day 1 through Day 78 (17 times)
|
Day 1 through Day 78 (17 times)
|
|
Assessment of 14C recovery in feces
Time Frame: Day 1 through Day 78 (16 times)
|
Day 1 through Day 78 (16 times)
|
|
Assessment of total 14C recovery (urine and feces combined) within 24 hours
Time Frame: Day 1 through Day 78 (17 times for urine and 16 times for feces)
|
Day 1 through Day 78 (17 times for urine and 16 times for feces)
|
|
Assessment of total 14C recovery (urine and feces combined) after Time of last quantifiable concentration (tlast)
Time Frame: Day 1 through Day 78 (17 times for urine and 16 times for feces)
|
Day 1 through Day 78 (17 times for urine and 16 times for feces)
|
|
Assessment of Pharmacokinetic profile of MDV3100 and metabolites in plasma
Time Frame: Day 1 through Day 78 (21 times)
|
PK of MDV3100, MDPC0001, and MDPC0002 in plasma based on validated LC-MS/MS methods:
The ratios of AUCMDV3100/AUC14C , AUCMDPC0001/AUCMDV3100 and AUCMDPC0001/AUC14C (and the same for MDPC0002) will be calculated |
Day 1 through Day 78 (21 times)
|
Assessment of Pharmacokinetic profile of MDV3100 and metabolites in urine
Time Frame: Day 1 through Day 78 (17 times)
|
PK of MDV3100, MDPC0001, and MDPC0002 in urine based on validated LC-MS/MS methods:
The ratios of AUCMDV3100/AUC14C , AUCMDPC0001/AUCMDV3100 and AUCMDPC0001/AUC14C (and the same for MDPC0002) will be calculated |
Day 1 through Day 78 (17 times)
|
Metabolic Profile: Profiling of possible metabolites of MDV3100 in plasma, urine, and feces
Time Frame: Day 1 through Day 78 (14 times)
|
Identification and possible quantification of metabolites in plasma, and if applicable, in urine and feces
|
Day 1 through Day 78 (14 times)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety as assessed by recording adverse events, laboratory assessments, vital signs and electrocardiograms (ECGs)
Time Frame: Day 1 through Day 78
|
Day 1 through Day 78
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 9785-CL-0001
- 2011-000089-37 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on MDV3100
-
Astellas Pharma Global Development, Inc.Medivation, Inc.WithdrawnMetastatic Castration-Resistant Prostate Cancer
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
-
Astellas Pharma IncPfizerCompletedCastration-resistant Prostate CancerJapan
-
Case Comprehensive Cancer CenterCompletedAdenocarcinoma of the ProstateUnited States
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedKidney Diseases | Healthy Subjects | Pharmacokinetics of MDV3100Moldova, Republic of
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedHealthy Subjects | Relative Bioavailability | Castration Resistant Prostate Cancer (CRPC) | MDV3100Germany
-
Zenith EpigeneticsEnrolling by invitation
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation TrustUnknownAdenocarcinoma of the ProstateUnited Kingdom
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.Active, not recruitingProstate Cancer | Cancer of the Prostate | Nonmetastatic Castration-Resistant Prostate CancerHong Kong, Canada, China, Germany, Spain, Netherlands, United Kingdom, Korea, Republic of, Taiwan, Australia, Denmark, France, United States, Singapore, Poland, Malaysia, Turkey, Belgium, Argentina, Thailand, Slovakia, Brazil, Finland, Ita... and more
-
OHSU Knight Cancer InstituteAstellas Pharma US, Inc.; Oregon Health and Science UniversityActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7United States